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Background: Metabolic syndrome (MetS) is characterized by central obesity, insulin resistance, dysglycemia, and a
pro-atherogenic plasma lipid profile. MetS creates a high risk for development of type 2 diabetes (T2DM) and car-
diovascular disease (CVD), presumably by altering inflammatory responses. Presently, it is unknown how the chronic
metabolic disturbances in acute hyperglycemia, MetS and T2DM affect the immune activity of peripheral blood
cells.
Methods: We performed genome-wide expression analysis of peripheral blood cells obtained from patients with
T2DM (n = 6) and age-, sex- , BMI- and blood pressure-matched obese individuals with MetS (n = 4) and lean healthy
normoglycemic controls (n = 3), both under fasting conditions and after controlled induction of acute hypergly-
cemia during a 70 min hyperglycemic clamp. Differential gene expression during fasting conditions was confirmed
by real-time PCR, for which we included additional age-, sex-, BMI-, and blood pressure-matched obese individuals
with (n = 4) or without (n = 4) MetS.
Results: Pathway and Gene ontology analysis applied to baseline expression profiles of peripheral blood cells from
MetS and T2DM patients revealed metabolic changes, highly similar to a reoviral infection gene signature in T2DM
patients. Transcription factor binding site analysis indicated that increased HIF-1α activity, a transcription factor in-
duced by either hypoxia or oxidative stress, is responsible for this aberrant metabolic profile in peripheral blood cells
from T2DM patients. Acute hyperglycemia in healthy controls resulted in reduced expression of cytotoxicity-related
genes, representing NK- and CD8+ cells. In obese controls, MetS and especially T2DM patients, baseline expression
of genes involved in cytotoxicity was already low, compared to healthy controls and did not further decrease upon
acute hyperglycemia.
Conclusions: The reduced activity of cytotoxic genes in T2DM is explained by chronic hyperglycemia, but its acute
effects are restricted to healthy controls. Genome expression of circulating leukocytes from T2DM patients differs
from MetS individuals by a specific reovirus signature. Our data thus suggest a role for suppressed anti-viral capacity
in the etiology of diabetes.* Correspondence: t.vanderpouwkraan@vumc.nl
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The incidence of metabolic syndrome (MetS) and type 2
diabetes (T2DM) with its associated mortality and mor-
bidity is rapidly increasing in the western world, leading
to an extensive medical and societal burden. MetS is
defined by a complex set of clinical parameters, which
all constitute risk factors for the development of T2DM.
These risk factors include central obesity, dyslipidemia
(raised triglycerides and lowered high-density lipoprotein
cholesterol), high blood pressure, and elevated fasting
plasma glucose levels [1].
High blood pressure, hyperglycemia and dislypidemia are
held responsible for the increased risk for cardiovascular
disease in MetS and T2DM patients, including microvascu-
lar complications (including retinopathy, nephropathy and
neuropathy) and atherosclerosis at the macrovascular level
[1–4]. Both high fasting glucose levels and impaired glucose
tolerance are associated with increased cardiovascular
events [5], while impaired glucose tolerance predicts car-
diovascular death [6]. Intensive glucose control, however,
only modestly reduces cardiovascular events [3, 6], indicat-
ing a more systemic dysregulation in these patients.
T2DM may develop after a stage of insulin resistance
in subjects with MetS. However, only approximately
one-third of obese, insulin-resistant individuals develop
T2DM because of an inability of beta cells to produce
sufficient amounts of insulin [7]. Systemic and local
activation of the immune system accompanies obesity,
and contributes to the development of insulin resist-
ance, T2DM and cardiovascular disease [8, 9]. It is not
entirely understood which mechanisms trigger the onset
of T2DM in subjects at risk, but inflammation is a
critical candidate. Pancreatic inflammation in T2DM
has been shown by increased local infiltration of macro-
phages in the beta cell areas [10, 11]. In animal models
for type 2 diabetes, characterization of the increased
infiltrating islet-associated macrophages indicated a pro-
inflammatory M1 phenotype, with production of IL-1β
and TNFα [12]. Adipose tissue may become a source of
inflammation as well, as adipocyte hypertrophy is asso-
ciated with increased macrophage accumulation, which
produce proinflammatory mediators such as TNFα and
IL-6, in obese individuals [8]. Trials aimed at inhibition
of the immune system by blockade of IL-1α and –β
signaling (anakinra) and inhibition of NFκB have shown
to reduce HbA1c levels suggesting an effect on beta
cell function in patients with T2DM [7, 12]. In animal
models, the IL-1 receptor antagonist reduced the num-
bers of macrophages in islet areas and improved insulin
sensitivity and beta cell function [12]. Infiltrating circu-
lating immune cells are thus important in the deve-
lopment of islet dysfunction, in inflammatory adipose
tissue, and in the development of atherosclerotic plaques
leading to macrovascular disease. The consequence ofacute hyperglycemia on circulating immune cells is largely
unknown, but a proinflammatory role for hyperglycemia
has been observed, because an oral glucose tolerance test
increases transcript levels for ICAM-1, TNFα, and IL-6 in
peripheral white blood cells from MetS subjects, but not
from healthy controls without MetS [13].
Thus blocking inflammation improves glucose toler-
ance in T2DM patients, but whether in vivo hypergly-
cemia is able to initiate the activation of the immune
system, without the influence of obesity, dyslipidemia,
and high blood pressure, is not known. Along this line,
it is thus also unknown whether the immune response
to acute hyperglycemia is different between healthy sub-
jects and MetS subject and T2DM patients.
Therefore we performed genome-wide expression pro-
filing to achieve an unbiased analysis of the effect of
hyperglycemia and T2DM on circulating immune cells.
Peripheral blood cells express a large proportion (ap-
proximately 80 %) of the genes encoded in the human
genome [14]. In addition, the changes in the expression
levels of individual genes reflects changes in the (micro)-
environment of peripheral blood cells and may also reflect
organ-specific changes to the same milieu [14], thus serving
as a diagnostic tool for a diseased state. Previous studies
using peripheral blood profiling revealed that in T2DM pa-
tients the mitochondrial oxidative phosphorylation pathway
was affected compared to younger lean controls [15]. This
finding is remarkable as a reduced expression of oxidative
phosphorylation genes was previously established in muscle
tissue from T2DM patients [16]. The immune system is af-
fected by metabolic changes in various organs, and vice
versa, the immune system influences metabolic parameters
such as insulin resistance. Because of this cross-talk the im-
mune system plays a central role in metabolic changes. To
be able to obtain a global and unbiased overview of the
changes in the immune system, in response to hypergly-
cemia and T2DM, we studied the alterations in gene ex-
pression in whole blood in T2DM patients in comparison
with age-, sex- blood pressure- and BMI- matched MetS
subjects and lean controls during fasting conditions and
after a well-controlled hyperglycemic clamp. We reasoned
that this approach may lead to an improved understanding
of the underlying pathology of T2DM and may give leads
for medical interventions. The comparison of our data with
expression data sets from other studies under various ex-
perimental conditions, using pathway analysis, allowed us
to identify novel pathological pathways.
Methods
Patients and controls
Individuals with MetS and patients with T2DM were
recruited by advertisements in local newspapers and
studied at the Clinical Research Unit of the Diabetes
Center, Department of Internal Medicine at the VU
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according to the criteria of the International Diabetes
Federation (IDF) [17]. In short, subjects were eligible
when they had a waist of ≥ 94 cm or more and addition-
ally, two or more of the following criteria: fasting triglycer-
ides ≥ 1.7 mmol/L, HDL cholesterol < 1.03 mmol/L, blood
pressure >130/85 mmHg (average of three measurements)
or treatment of previously diagnosed hypertension; fasting
plasma glucose level (FPG) ≥ 5.6 and < 7.1 mmol/L.
The response to acute elevations of blood glucose
levels in T2DM (n = 6), MetS (n = 4) and controls (n = 3)
was measured during the hyperglycemic portion of a com-
bined euglycemic-hyperinsulinemic and hyperglycemic-
arginine clamp, as described earlier [18]. In short, following
the 2 h euglycemic hyperinsulinemic part of the combined
clamp (glucose 5 mmol/L, insulin 600 pmol/L), a 1 h rest
period was included to clear the exogenously administered
insulin. Thereafter, a hyperglycemic clamp was started,
keeping blood glucose at 15 mmol/L for MetS and T2DM
and at 10 mmol/L in controls. Blood samples were taken at
fasting conditions, i.e. 5 min before the initiation of the
clamp and at 70 min after the start of the glucose clamp in
patients and controls. All T2DM patients were on metfor-
min monotherapy. Research involving human subjects
(including human material or human data) has been per-
formed with the approval of our local Medical Ethical
Committee (in Dutch: Medisch Ethische Toetsingscom-
missie or METc, of the VU Medical Center (VUmc)).
The research carried out on humans is in compliance
with the Helsinki Declaration. Written informed con-
sent was obtained from each participant.
Gene expression profiling
Blood was withdrawn in PAXgene tubes (PreAnalytix,
GmbH, Germany) at baseline, i.e. 5 min before the glu-
cose clamp test, and 70 min after the hyperglycemic
clamp of 10 mm/L l for controls or 15 mm/L for T2DM
patients and individuals with MetS .
Total RNA was isolated from peripheral blood using
the PAXgene RNA isolation kit according to the manu-
facturers’ instructions including a DNAse (Qiagen, Venlo,
The Netherlands) step to remove genomic DNA. RNA
samples were further processed by ServiceXS (Leiden,
The Netherlands). Amplification was performed using
the Ambion® Illumina TotalPrep RNA Amplification Kit
(Ambion, # IL1791), resulting in biotinylated, amplified
cRNA. Labelled RNA samples were hybridized to Sentrix
Human HT12v3 Expression bead chip arrays (Illumina,
San Diego, CA). Signal was developed with streptavidin-
Cy3 and the BeadChip was scanned with the Illumina
BeadArray Reader, which is a two-channel, 0.8 μm reso-
lution confocal laser scanner, followed by feature extraction.
Bead summary intensities were log2-transformed and nor-
malized using quantile normalization [19].Statistical and biological pathway analysis
We used Significance Analysis of Microarrays (SAM)
[20] for the identification of over- or under-expressed
genes after the glucose clamp, applying a two-class paired
comparison between samples before and after the clamps.
For identification of differences between study groups, we
performed a two-class unpaired comparison between
MetS - and T2DM individuals. Genes with a false discov-
ery rate (FDR) < 5 % were considered significantly differ-
ent. Hierarchical clustering [21] of samples was used to
visualize the correlation of co-expressed genes in Tree-
view. For this purpose the genes were expressed relative to
the median expression level in all samples (median cen-
tered data). For an interpretation of the biological pro-
cesses that are represented by the genes that show a
significantly different level of expression after glucose
clamp or between patient groups we used Gene Ontology
analysis using the PANTHER-v8.1 (Protein ANalysis
THrough Evolutionary Relationships) Classification Sys-
tem at [22], a curated database of protein families, trees,
subfamilies and functions. PANTHER uses the binomial
statistics tool to compare our gene list to a reference list
(NCBI: Homo sapiens genes) to determine the statistically
significant over-representation of functional groups of
genes. Pathway level analysis [23] of gene expression data
was performed by gene set enrichment analysis (GSEA).
Pathways comprise lists of genes with a connected bio-
logical background and can be used from several sources
such as Kyoto Encyclopedia of Genes and Genomes
(KEGG), Biocarta, and Reactome databases, user-defined
pathways and previously published expression data sets as
provided by the Broad institute in the Molecular Signa-
tures database, as described in [24]. We made use of a
combination of these pathways provided by the Broad In-
stitute (C2v2 curated geneset), with a minimal geneset size
of ten genes, using 1,000 gene set permutations to correct
for multiple testing. This type of analysis allows the com-
parison of our own data with experimental expression data
generated by others in an unbiased fashion. Transcription
factor binding site analysis was performed on the 500 bp
upstream regulatory region of the differentially expressed
genes between T2DM and MetS. Lists of significantly dif-
ferent expressed genes between clinical samples were ana-
lyzed for enriched transcription factor binding sites by
whole genome rVISTA software at [25], using the Transfac
database of all transcription factor binding sites (TFBS)
conserved in the human to mouse whole genome align-
ment of March 2006.
RNA isolation, cDNA synthesis, quantitative real-time PCR
Total RNA was isolated from peripheral blood using the
PAXgene RNA isolation kit according to the manufac-
turers’ instructions including a DNAse (Qiagen, Venlo,
The Netherlands) step to remove genomic DNA. RNA
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RNA purity and concentration was measured using
NanoDrop ND-1,000 Spectrophotometer (Thermo Sci-
entific, Breda, The Netherlands). cDNA was synthesized
from 500 ng total RNA per sample using RevertAid™ H
Minus First Strand cDNA Synthesis Kit (Thermo Fisher
Scientific, Waltham, MA, USA) according to the manu-
facturer’s recommendations. Quantitative real-time poly-
merase chain reaction (PCR) was performed in an ABI
PRISM 7900HT system (Applied Biosystems, Foster City,
CA, USA), using primers designed by Primer Express
version 2.0 (Applied Biosystems):
Briefly, in a 10 μl reaction volume, 4 μl of diluted
cDNA, 5 μl SYBR Green PCR Master Mix (Applied Bio-
systems), and 0.5 uM of each gene-specific primers were
mixed. Gene expression levels were calculated using an
arbitrary standard curve and normalized to the human
housekeeping gene β-actin. Comparisons were performed
using Student’s t-test (two-sided). Differences were consid-
ered statistically significant if probability values (P) were
less than 0.05. Results are presented as mean ± standard
error of the mean (SEM).Results
Gene expression in peripheral blood cells from T2DM
patients differs markedly from both MetS individuals and
healthy controls
We compared the baseline gene expression levels of per-
ipheral blood cells from six patients with T2DM to four
subjects with MetS, who showed no difference in age, sex,
BMI, waist circumference and blood pressure (Table 1).
As expected, T2DM patients showed higher fasting plasma
glucose (FPG), glycated hemoglobin A1C (HbA1c),
while the lipid profile also differed, with higher trigly-
ceride - and lower HDL levels in T2DM, compared to
MetS. For comparison, we included healthy lean con-
trols with normal fasting glucose levels and lipid profile,
albeit of younger age.Applying statistical analysis of microarray data (SAM)
[20], we identified many genes that were expressed at
different levels in T2DM patients versus MetS subjects.
We identified 591 genes which were expressed at higher
levels and 260 genes expressed at lower levels in T2DM,
compared to MetS individuals (at a false discovery rate,
FDR of < 5 %, see Additional files 1 and 2). In Fig. 1 the
differential transcript expression levels in circulating
blood cells are visualized after hierarchical clustering of
the genes. Although the lean controls were not part of
this statistical analysis, we visualized their expression
levels for the genes that were differentially expressed be-
tween T2DM and MetS to mark the strong resemblance
of lean controls with the MetS subjects. As expected, an
increased expression of proinflammatory marker genes
was detected in T2DM patients, compared to MetS.
These genes include: S100A12 (or EN-RAGE, extracellu-
lar newly identified receptor for advanced glycation end
products-binding protein, (2.6 fold increase in T2DM,
FDR = 1.97 %), CD164 (2.75 fold increase, FDR < 0.1 %),
TLR1 (2.8 fold increase, FDR <0.1 %). In addition,
T2DM patients expressed higher levels of the regulator
of energy balance, leptin (1.5 fold increase, FDR = 4.1 %),
and of the anti-oxidant gene catalase (2.0 fold increase,
FDR = 4.1 %).
Pathway and gene set analysis identifies a reovirus
signature in T2DM patients
The Panther classification system was used to determine
which biological processes were represented by the dif-
ferentially expressed genes in the T2DM patients versus
MetS individuals by applying the statistical overrepresen-
tation test (Fisher’s exact). Both the group of genes that
were expressed at higher levels and the panel of genes
which were expressed at lower levels were involved in
broadly defined metabolic processes (Table 2). These
data indicate that a disturbance of systemic metabolism
is reflected in gene expression patterns in peripheral
blood cells in patients with T2DM. Applying the same
analysis in T2DM patients versus controls, we also de-
tected significant metabolic differences, albeit at lower
levels of statistical significance, due to the low number
of controls.
To obtain more insight into the pathology behind the
differences in gene expression, we applied pathway ana-
lysis using Gene Set Enrichment Analysis (GSEA, [23]).
This analysis allowed us to compare a wide array of pub-
lished genome expression data sets, defined by experi-
mental conditions or disease states, to our own data
(Table 3 and Fig. 2). Strikingly, from over 1,500 pathways
(GSEA functional gene set, C2v2) analyzed, the most sig-
nificant T2DM-associated gene set, comprised genes
which were previously identified as being upregulated by
reovirus infection [26]. Concordantly, also one of the most
Table 1 Characteristics of the groups of patients for which genome-wide expression profiling was performed
T2DM MetS Healthy controls p-value p-value p-value
n = 6 n = 4 n = 3 T2DM vs C MetS vs C MetS vs T2DM
Age (years) 59.2 60.9 22.7 <0.0001 0.001 0.76
Sex (m/f) 6/0 3/1 3/0 1 1 0.40
Height (cm) 172.2 174.9 187.3 0.001 0.09 0.59
Weight (kg) 84.2 83.4 74.2 0.14 0.36 0.91
BMI (kg/m2) 28.5 27.1 21.1 0.02 0.03 0.56
Waist (cm) 102.1 97.6 79.2 0.02 0.07 0.57
Syst. BP (mm Hg) 143.5 133.7 114.7 0.02 0.06 0.32
Diast. BP (mm Hg) 85.3 84.2 70 0.03 0.06 0.87
FPG (mmol/l) 8.4 6.7 4.6 0.0002 0.0008 0.005
HbA1c (%) 6.6 5.9 na na na 0.10
Tot Chol (mmol/l) 4.8 5.2 4.4 0.51 0.24 0.48
HDL (mmol/l) 1.1 1.7 1.6 0.006 0.52 0.002
LDL (mmol/l) 3 3 2.4 0.34 0.25 0.97
TG (mmol/l) 1.9 1 0.9 0.02 0.66 0.01
BMI; body mass index, Syst BP; systolic blood pressure, Diast BP; diastolic BP, FPG; fasting plasma glucose, HbA1c; hemoglobin A1c, Tot Chol; Total cholesterol,
HDL; high density lipoproteins, LDL; low density lipoproteins, TG; triglycerides, na; not available, p-values were calculated by Student’s T-test, or Fisher’s exact for
sex. p values <0.05 were considered significant (highlighted in bold)
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lower levels in T2DM vs MetS patients were genes down-
regulated by reovirus infection. The reovirus signature was
generated in vitro in Human Embryonic Kidney (HEK293)
cells. Because of this unexpected finding we searched for
other published virus-induced genesets derived from
infected circulating blood cells, thus more comparable to
our study. We found two more relevant and more physio-
logical data sets, i.e. ex vivo virus infection-induced pro-
files in PBMC from infected children. One set was derived
from children infected with a closely related RNA virus,
Rotavirus, another member of the Reoviridae family [27].
Another set was derived from a study in which infection
with a more distantly related RNA virus, the Influenza
virus was analyzed [28]. In both studies gene expression in
PBMC from infected children was compared to PBMC
from healthy children. The Rotavirus signature was also
significantly associated with T2DM, Rotavirus-induced
genes were upregulated in T2DM patients (Fig. 2 and
Table 3), while Rotavirus-repressed genes were downregu-
lated in T2DM patients. The signature of the Influenza
virus was not associated with T2DM (Influenza-induced
genes, FDR = 0.43 (or 43 %), Influenza-repressed genes,
FDR = 0.14, data not shown). Because type I interferon is
typically induced by viral infections we also included an
ex vivo type I interferon-induced geneset in PBMC from
IFNα-treated patients [29]. The type I IFN-induced gene-
set was also significantly increased in T2DM (Table 3 and
Fig. 2). The IFN response in T2DM was also indicated bythe significant geneset: GRANDVAUX_IRF3_UP, contain-
ing genes up-regulated in Jurkat T cells by expression of a
constitutively active form of IRF3, which is normally acti-
vated during viral infections and induces type I IFNs [30].
In Fig. 2 the reoviral signatures are represented, showing
the enriched genes: 73 reoviral genes were enriched in
T2DM; expressed at high levels in T2DM out of the 227
reovirus-induced genes and also 73 reovirus-repressed
genes were enriched; expressed at low levels in T2DM out
of the 214 reovirus-repressed genes. Similar results are
shown for the Rotavirus- and IFNα-induced signatures.
Thus, gene expression profiles in peripheral blood cells in-
duced by T2DM show a significant and specific pattern,
similar to the modulatory effect of reovirus infection. We
included a Venn diagram (Fig. 3), visualizing the overlap
of the enriched genes in T2DM patients for the four virus
infection-associated genesets. This diagram shows that the
genes induced by the three virus types all contain IFNα-
induced genes, in particular Influenza (11 out of 28 genes),
and that 57 genes are uniquely induced by reovirus.
Although the healthy controls were not matched for
age and BMI, we did perform pathway analysis and con-
firmed the previously reported reduced expression of
genes representing electron transport chain and oxida-
tive phosphorylation in T2DM compared to significantly
younger lean controls (FDR < 0.015, data not shown)
[15], while the reovirus signatures were also highly sig-
nificantly present when we compared T2DM to young







Fig. 1 Visualization of 851 transcripts with significant different
expression levels (FDR < 5 %) in circulating blood cells between
patients with T2DM and subjects with MetS. Although the healthy lean
controls were not included in the analysis, their profile is included for
comparison. Blue indicates relative low expression, yellow represents a
relative high expression, black represents intermediate expression
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metabolic gene profiles in peripheral blood cells
We next analyzed all genes which were upregulated by
reovirus (n = 226), as published [26] and for the genes
which were both upregulated by reovirus and by T2DM
(n = 73), as identified by our GSEA analysis forinvolvement in metabolic processes. The same gene
ontology analysis was performed for the genes which
were downregulated by reovirus. In all of these analyses,
metabolic processes were (among) the most significant
processes represented by all gene sets, indicating that
reovirus induces similar metabolic changes as the meta-
bolic abnormalities observed in T2DM patients (Table 4).
The 57 unique reovirus-induced genes, indicated in
Fig. 3, indeed represent the metabolic processes from
Table 4; nucleobase, nucleoside, nucleotide and nucleic
acid metabolic process, primary metabolic processes,
metabolic processes, protein amino acid phosphorylation
(all p < 0.001) and monosaccharide metabolic process (p =
0.004).
To identify which factor(s) may have caused the al-
tered gene expression in T2DM patients, we performed
a transcription factor binding site analysis (Table 5). The
most significant enriched binding site in the upstream
regulatory region of genes which were expressed at
higher levels in T2DM patients versus MetS was HIF1
(p = 1.25 × 10−12, Table 5A). HIF1 comprises the binding
site for the heterodimeric protein consisting of HIF-1α
and the constitutively expressed HIF-1β (also termed
ARNT) and is a major regulator of metabolic processes
as its activity is controlled by either hypoxia or oxidative
stress. Interestingly, also ARNT binding sites were sig-
nificantly overexpressed in this gene set (p = 2.33 × 10−6,
Table 5A). In a comparison between T2DM patients and
lean controls, the significantly higher expressed genes in
T2DM also showed enriched binding sites for HIF1 and
ARNT (p = 1 × 10−16 and p = 7.6 × 10−9 respectively),
for lower expressed genes HIF1 was again also enriched
(p = 7.1 × 10−5, data not shown). Our data thus indicate
that HIF-1α/ARNT may regulate the expression of the
genes involved in metabolic processes as identified from
the gene ontology analysis.
Identification of a cytotoxicity profile with a blunted
response to in vivo acute hyperglycemia in T2DM
blood cells
To study the impact of acute hyperglycemia on the
expression patterns in circulating leukocytes in the re-
spective study groups, we analyzed alterations in gene
expression profiles in T2DM patients, individuals with
MetS and healthy controls in response to a hyperglycemic
clamp (paired analysis, ANOVA). Only a limited number
of genes per group changed in expression after exposure
to acute elevations of blood glucose, and none of the genes
showed altered expression upon hyperglycemia in all three
groups (Table 6). The T2DM group hardly responded to
the hyperglycemic clamp as only 3 genes were down-
regulated (TSC22D3, DUSP1, and MCL1). In individ-
uals with MetS, four genes were down-regulated after
the 70 min hyperglycemic clamp, including C1orf162,
Table 2 Gene ontology analysis of genes expressed at higher and lower levels in T2DM vs MetS
GO analysis of genes expressed at higher levels in T2DM vs MetS:
Biological process nr in genome nr sign genes p-value
Metabolic process 8,127 183 5.13E-04
Primary metabolic process 7,813 175 1.06E-03
Protein transport 1,542 44 3.29E-03
Intracellular protein transport 1,542 44 3.29E-03
Cell cycle 1,602 45 3.94E-03
GO analysis of genes expressed at lower levels in T2DM vs MetS:
Metabolic process 8,127 113 1.15E-06
Primary metabolic process 7,813 109 2.04E-06
Translation 453 14 1.75E-04
Organelle organization 295 11 1.83E-04
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 3,782 58 2.04E-04
Establishment or maintenance of chromatin architecture 269 10 3.68E-04
Protein metabolic process 3,178 49 6.75E-04
Transcription from RNA polymerase II promoter 2,214 37 8.63E-04
RNA metabolic process 663 16 9.19E-04
Transcription 2,224 37 9.36E-04
Cell cycle 1,602 29 1.02E-03
Nuclear mRNA splicing, via spliceosome 371 11 1.21E-03
Cellular component organization 1,255 24 1.39E-03
mRNA processing 456 12 1.98E-03
Hemopoiesis 183 6 9.83E-03
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significantly up-regulated by high glucose levels in the
MetS group: IL-8 en HIV-1 Tat specific factor one
pseudogene (LOC401233). In the control group we
identified nine genes which were down-regulated after
in vivo exposure to high glucose, while none of the
genes showed up-regulation. Remarkably, five out of
nine glucose-responsive down-regulated genes in con-
trols have a documented role in immune cell-induced
cytoxicity: chloride intracellular channel 3 (CLIC3),
killer cell immunoglobulin-like receptor, two domains,
long cytoplasmic tail, 4 (KIR2DL4), perforin 1 (PRF1),
Granzym B (GZMB) and granulysin (GNLY). These
genes are typically expressed in cells with cytotoxic
functions, like NK cells [31] and CD8+ T cells [32, 33].
Overall, the limited overlaps in response to high glucose
between the three groups places the MetS group as an
intermediate between controls and T2DM patients,
corresponding with their intermediate clinical parame-
ters (Table 1). Because the cellular composition will
affect the gene expression profile, we included cell-
specific genesets in the pathway analysis; T cells, CD8 T
cells, granulocytes, B cells, and lymphocytes [34], and
our own previously published cytotoxic NK cell dataset
[35]. Including these genesets in our pathway analysisled to the identification of the cytotoxic cell subset as
the most significant geneset with reduced expression in
T2DM patients (Fig. 2 and Table 3). In addition, profiles
specific for cytotoxic CD8 cells (Table 3) and to a lesser
extend B cells (data not shown, FDR = 0.03) were
reduced in the T2DM patients compared to MetS.
Thus, the genes which were downregulated by high
glucose levels in controls were already expressed at
lower levels in T2DM patients, most likely due to
chronic high glucose levels. The five cytotoxicity-related
genes that were downregulated by hyperglycemia in con-
trols all showed the same expression pattern across the
patient groups. We therefore averaged the expression of
these five genes in each individual at each time point
to visualize the transcript levels (Fig. 4). The average
expression at baseline was 2.3 fold lower in T2DM
compared to controls (p = 0.003) and MetS subjects
showed a 1.5 fold lower expression compared to controls
(p = 0.03). To establish whether obesity, without MetS
was also affecting the expression levels of these cytotoxic
genes, and to confirm the observed baseline differences
by an independent technique, we performed baseline
gene quantification by real-time PCR in a larger sample
set (Table 7). We included four age-, sex-, blood pressure-,
and BMI- matched (obese) controls (not fulfilling the
Table 3 Gene set enrichment analysis
A. Significant gene sets expressed at higher levels in
T2DM vs MetS subjects
Name Size NES NOM p-val FDR q-val
DEBIASI_REOVIRUS_HEK293_UP 227 −2.08 0.000 0.024
JI_IFNA_INDUCED_PBMC_EX_VIVO 325 −2.05 0.000 0.024
ROTH_HTERT_UP 14 −2.03 0.000 0.020
FLECHNER_KIDNEY_TRANSPLANT_
WELL_UP
496 −1.98 0.000 0.034
UVB_SCC_UP 83 −1.96 0.000 0.042
MMS_HUMAN_LYMPH_LOW_
4HRS_DN
16 −1.94 0.000 0.046
GRANDVAUX_IRF3_UP 13 −1.94 0.000 0.041
CHEN_HOXA5_TARGETS_UP 195 −1.92 0.000 0.045
DORSAM_HOXA9_DN 30 −1.92 0.000 0.042
DORSAM_HOXA9_UP 32 −1.89 0.002 0.062
HDACI_COLON_SUL12HRS_DN 26 −1.88 0.000 0.059
WANG_ROTAVIRUS_INFECTION_
PBMC_UP
48 −1.88 0.000 0.056
MMS_MOUSE_LYMPH_HIGH_
4HRS_UP
35 −1.87 0.000 0.062
TAKEDA_NUP8_HOXA9_3D_DN 28 −1.86 0.002 0.069
ZUCCHI_EPITHELIAL_UP 42 −1.84 0.000 0.082
B. Significant gene sets expressed at lower levels
in T2DM vs MetS subjects
Name Size NES NOM p-val FDR q-val
POUWKRAAN_CYTOTOXIC_CELLS 57 2.29 0 0.000
DEBIASI_REOVIRUS_HEK293_DN 214 2.10 0 0.003
BASSO_REGULATORY_HUBS 129 2.09 0 0.002
LIN_WNT_UP 51 2.08 0 0.002
ROSS_MLL_FUSION 73 2.05 0 0.002
BRCA1_OVEREXP_DN 102 2.01 0 0.005
PALMER_CD8_CELLS 16 2.01 0 0.004
YU_CMYC_DN 44 2.01 0 0.004
FALT_BCLL_UP 43 2.00 0 0.004
WANG_ROTAVIRUS_INFECTION_
PBMC_DN
133 1.97 0 0.007
FERRANDO_MLL_T_ALL_UP 86 1.97 0 0.006
DNA_REPLICATION_REACTOME 44 1.88 0 0.025
ET743_HELA_DN 17 1.87 0 0.027
NING_COPD_UP 141 1.86 0 0.030
NAKAJIMA_MCSMBP_MAST 47 1.86 0 0.029
The top 15 significant pathways are listed, ranked on Normalized Enrichment
Score (NES)
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jects. We quantified the four most significantly downregu-
lated genes after hyperglycemia (selected from Table 6),
which all showed a similar expression pattern among the
four groups (Fig. 5). We confirmed that expression levelswere highest in the lean control group, compared to all
other groups (p < 0.05 for CLIC3 and Granzym B) or com-
pared to obese controls and MetS (p < 0.05 for Perforin).
Expression levels were again lowest in T2DM, compared
to MetS and controls, reaching statistical significance for
CLIC3 and Granzyme B (p < 0.05). Obese controls were
not significantly different from MetS subjects or T2DM
patients, although the sample size was small (n = 4).
Our results indicate that cytotoxic genes are downreg-
ulated in peripheral blood cells by high glucose levels,
are expressed at lower levels in T2DM patients com-
pared to MetS subjects and lean controls. Furthermore,
these genes may also be affected by obesity and age.
Discussion
Peripheral blood cells in T2DM are chronically exposed
to abnormally high levels of glucose, due to the beta cell
dysfunction in the presence of insulin resistance.
After imposing acute hyperglycemia in vivo in control
individuals by applying a 70 min hyperglycemic clamp,
we observed a markedly reduced expression of
cytotoxicity-related genes. In T2DM patients the expres-
sion levels of these cytotoxic genes were already low,
and were hardly affected by the hyperglycemic clamp.
MetS subjects showed an intermediate response. We
thus provide evidence that the reduced expression of
cytotoxic genes is a direct consequence of high glucose
levels. We did not observe a difference in baseline cyto-
toxic gene expression between age- and BMI-matched
obese controls and MetS subjects, indicating that age
and obesity may contribute to the low expression of
cytotoxicity genes. In mice, cytotoxic gene expression
declines with old age which is correlated with a reduced
cytolytic capacity of cytotoxic T cells [36]. For humans,
it has been reported that the functional capacity of
virus-specific cytotoxic CD8+ T cells diminishes after the
age of sixty [37]. High glucose levels may therefore ac-
celerate the decline of functional CD8+ cells in MetS
and especially T2DM patients (mean age was 59–60
years). This decline may influence the risk of cardiovas-
cular disease, as experimental injury-induced arterial
neointima formation is reduced by the most lytic frac-
tion of CD8+ cells, due to lysis of vascular smooth
muscle cells [38, 39], while CD8+ cells also mediate the
athero-protective effect of immunization with an ApoB-
100 peptide [39].
Our pathway analysis confirmed a low expression of
effector cytotoxic cells in T2DM patients compared
to MetS subjects, most likely indicating a reduced
number of circulating cytotoxic cells, as was observed
in azathioprine-treated Crohn’s Disease patients [35].
A reduced lytic cell activity, may lead to an increased
vulnerability for viral infections and tumor development
in the host. CD8+ cytotoxic T cells and NK cells are
 decudni-ANFIpU_surivoeR nwoD_surivoeRpU_surivatoR nwoD_surivatoRsllec cixototyC
MetS T2DMMetS T2DMT2DMMetS MetS T2DMT2DMMetST2DMMetS
Fig. 2 GSEA analysis identifies reovirus-regulated gene sets in T2DM vs MetS patients and reduced expression of cytotoxic genes in T2DM.
Visualization of the enriched Reoviridae family-upregulated - and downregulated genes, IFNA-induced genes, and specific cytotoxic cell genes in
T2DM patients. Blue indicates relative low expression, red represents a relative high expression
Fig. 3 Venn diagram of enriched genes in T2DM from 4 genesets. Visualization of the overlap of the enriched genes in T2DM patients for the
four virus infection-associated genesets
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Table 4 Gene ontology (GO) analysis of genes related to reovirus infection [26]
GO analysis of genes expressed at higher levels in reovirus-infected cells: Upreg. in RI Upreg in RI, and T2DM
Biological Process nr in genome nr sign genes p-value nr sign genes p-value
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 3782 75 7.78E-09 22 5.74E-03
primary metabolic process 7813 120 9.01E-08 40 7.65E-04
metabolic process 8127 120 1.03E-06 40 1.87E-03
response to interferon-gamma 113 9 3.90E-06 5 4.46E-05
intracellular signaling cascade 1492 34 1.68E-05 11 1.16E-02
monosaccharide metabolic process 202 10 6.56E-05 6 6.80E-05
protein amino acid phosphorylation 654 19 7.17E-05 12 1.97E-06
response to stress 496 16 8.33E-05 6 6.86E-03
MAPKKK cascade 454 15 1.07E-04 5 1.93E-02
cell cycle 1602 31 7.28E-04 9 9.23E-02
protein modification process 1330 23 1.32E-02 13 4.87E-04
GO analysis of genes expressed at lower levels in reovirus-infected cells: Downreg. in RI Downreg in RI, and T2DM
Biological Process nr in genome nr sign genes p-value nr sign genes p-value
primary metabolic process 7813 110 3.70E-06 41 2.28E-03
metabolic process 8127 113 4.35E-06 41 5.27E-03
cell adhesion 1301 29 4.56E-05 11 7.40E-03
protein modification process 1330 29 6.72E-05 11 8.66E-03
protein amino acid phosphorylation 654 18 1.17E-04 7 9.91E-03
GO analysis was performed on genes which were expressed at higher or lower levels after reovirus infection (RI), and of reovirus-regulated genes that were either
up- or down regulated in T2DM vs MetS individuals, identified by gene set enrichment analysis. P-values < 10E-4 are included if reached for one of the analyses
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their lytic activity (mediated by granzymes, granulysin and
perforin) and non-lytic mechanisms through release of
anti-viral cytokines [40, 41]. Thus a low activity of cyto-
toxic cells, indicated by the reduced expression of these
genes in T2DM patients may cause an impaired response
to cancer and viral infections. The incidence of cancer is
indeed higher in subjects with MetS and T2DM [42].
For hepatocellular carcinoma in chronic hepatitis C
patients the increased incidence in T2DM patients
is also related to high concentrations of glycosylated
hemoglobin (HbA1c), corresponding with our finding
that hyperglycemia reduces cytotoxic genes. Active viral
infections may also be more common in diabetes, sug-
gested by the increased incidence of cytomegalovirus in
atherosclerotic lesions in arteries from patients with
T2DM [43], a virus which usually reactivates in im-
munocompromised hosts. The detrimental effect of ele-
vated glucose levels on anti-viral responses has been
previously observed in type I diabetes patients, which
showed a decreased in vivo T cell response to influenza
antigen [44] and decreased in vitro cytotoxic T cell re-
sponse to influenza vaccination [45]. Both phenomena
were associated with high concentrations of HbA1c,
while B cell responses were normal.
However, other viral infections may be easily over-
looked, because many-, including reovirus infections,commonly cause only mild symptoms or follow a sub-
clinical course.
Our pathway analysis indicated that the expression
profile of T2DM patients contained a viral signature of
the Reoviridae family comprising reovirus [26], and
Rotavirus [27]. The reovirus signature is derived from
in vitro infection of human embryonic kidney cells,
while the Rotavirus signature is derived from PBMC
from Rotavirus- infected children. Nevertheless, the
reovirus signature is more significant. The other virus-
regulated gene sets included in our analysis; Influenza-,
forty CMV-, two HPV- and one HCV-regulated sets of
genes were not significantly associated with T2DM, indi-
cating a certain level of specificity for reovirus. Reovirus
is a double-stranded RNA virus that is believed to cause
mild infections of the upper respiratory and gastrointes-
tinal tract of humans, while Rotavirus (RV) is another
ubiquitous double-stranded RNA virus, which may also
cause gastroenteritis. Interestingly, reoviruses are known
to experimentally induce type 1 diabetes, by inducing in-
sulitis, reduction in insulin content of the pancreas and
abnormal glucose tolerance [46, 47]. Likewise, Rotavirus
infection is associated with a faster progression of diabetes
in diabetes-prone mice [48] and with pancreatic apoptosis
and hyperglycemia in nondiabetes-prone mice [49]. Previ-
ous studies already pointed towards a role for viruses in
development human T1DM. For T1DM it is hypothesized
Table 5 Transcription factor binding site analysis of differentially expressed genes in T2DM versus MetS patients
A. Analysis of genes that were expressed at significantly higher levels in T2DM versus MetS patients
Name Number of hits in the submitted regions Total number of hits on genome p-value
HIF1 148 4,853 1.25E-12
MYC 214 9,078 1.08E-07
STRA13 25 466 3.06E-07
ARNT 46 1,326 2.33E-06
XBP1 67 2,323 8.31E-06
SREBP1 74 2,807 5.46E-05
ATF4 176 8,147 1.33E-04
HES1 183 8,691 3.37E-04
E2F1DP1 302 15,241 3.47E-04
DEC 79 3,322 6.99E-04
B. Analysis of genes that were expressed at significantly lower levels in T2DM versus MetS patients
Name Number of hits in the submitted regions Total number of hits on genome p-value
GABP 50 2,358 2.64E-08
PEA3 112 7,400 5.40E-08
CETS168 79 4,918 4.95E-07
AR 71 4,314 7.78E-07
HIF1 73 4,853 1.17E-05
DEC 54 3,322 2.04E-05
E2F1DP1 180 15,241 6.43E-05
TFE 58 3,881 1.00E-04
MYC 113 9,078 2.10E-04
NRF1 19 919 6.45E-04
E2F1DP2 140 12,122 8.78E-04
Significant binding sites are shown with a p-value <0.001
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lar enteroviruses are strong candidates [50], because there
is a clinically significant association between enterovirus
infection and T1DM. In accordance with this hypothesis,
enterovirus (echovirus) is able to infect and destroy hu-
man beta cells in vitro [51]. Additional evidence is pro-
vided by the fact that in more than half of the human
T1DM patients, beta cells show clear enteroviral capsid
protein vp1 expression, indicative for enteroviral infection,
while only 6 % of controls are marginally positive. Interest-
ingly, also 10 out of 25 T2DM patients were positive for
enteroviral capsid protein vp1 expression, suggesting that
viral infections may contribute to beta cell loss and insulin
dependency in T2DM as well [52]. Our results support
the hypothesis, using an unbiased approach, that viral in-
fections (potentially reovirus), may contribute to develop-
ment of insulin-dependent diabetes in T2DM patients.
The fact that the reovirus signature was present in
T2DM but not in MetS subjects is in line with the
observation that inflammation in general contributes to
the development of T2DM [10–12], and supports the
finding that inhibition of inflammation (by blockade ofIL-1 signaling) improves HbA1c levels in T2DM patients
without changing insulin sensitivity, but not in non-
diabetic subjects with MetS [53]. Inhibition of inflamma-
tion therefore most likely has beneficial effects on insulin
production in T2DM patients only.
Apart from the viral signature in T2DM, systemic in-
flammation was also indicated by the increased tran-
script expression of S100A12/ENRAGE, corresponding
with the reported increased serum levels of S100A12/
EN-RAGE in T2DM patients [54], CD164, a HIF-1α-
response gene [55], encoding a sialomucin expressed on
peripheral blood monocyte, involved in adhesion [56],
and TLR1. Interestingly, mRNA encoding for the appe-
tite hormone leptin was also increased in T2DM vs
MetS, which is normally expressed in adipose tissue, and
at higher levels per gram tissue from obese subjects
compared to lean individuals [57, 58].
In search of transcription factors that may have caused
the altered expression profile in T2DM patients, we
identified highly enriched transcription factor binding
sites for HIF1 and ARNT in genes with an aberrant ex-
pression compared to MetS patients (and lean controls).
Table 6 Genes with altered expression after in vivo exposure to high blood glucose
Downregulated genes after hyperglycemia
Gene name Symbol Controls (n = 3) MetS (n = 4) T2DM (n = 6)
FC q-value FC q-value FC q-value
Granzyme B GZMB 0.42 0.00 0.71 0.00 0.97 98.95
Granulysin GNLY 0.47 0.00 0.92 88.23 1.07 96.96
Perforin 1 PRF1 0.48 0.00 0.77 75.30 0.96 98.64
Fibroblast growth factor binding protein 2 FGFBP2 0.50 0.00 1.00 99.70 1.17 96.96
Chloride intracellular channel 3 CLIC3 0.56 0.00 0.95 93.51 1.03 98.21
Killer cell immunoglobulinlike receptor, two domains, long cytoplasmic tail, 4 KIR2DL4 0.62 0.00 0.89 65.06 1.05 96.96
Chromosome 1 open reading frame 162 C1orf162 0.66 0.00 0.75 0.00 0.90 81.90
Cystatin F (leukocystatin) CST7 0.67 0.00 1.01 97.65 1.03 98.21
Galectin 1 LGALS1 0.68 0.00 0.97 98.10 0.97 98.72
FK506 binding protein 5 FKBP5 0.68 9.78 0.51 0.00 0.71 37.55
TSC22 domain family, member 3 TSC22D3 0.73 10.48 0.70 0.00 0.64 0.00
Dual specificity phosphatase 1 DUSP1 1.02 96.30 0.71 70.35 0.69 0.00
Myeloid cell leukemia sequence 1 (BCL2related) MCL1 1.00 97.20 0.89 67.05 0.81 0.00
Upregulated genes after hyperglycemia
Interleukin 8 IL8 1.24 66.30 1.44 0.00 1.46 22.49
HIV1 Tat specific factor 1 pseudogene LOC401233 1.18 67.90 1.24 0.00 1.07 96.96
FC indicates fold change compare to baseline levels. q-value indicates the false discovery rate (%). Significant changes are indicated in bold (q < 5 %). Gene
symbols indicated in bold are cytotoxicity related, and visualized in Fig. 4
Fig. 4 Visualization of the reduced expression of cytotoxicity related genes, in healthy controls after hyperglycemia (derived from Table 6). In
patients with T2DM the expression is already low and does not further decrease after hyperglycemia. The average expression of 5 cytotoxicity
related genes measured by microarray analysis is shown in controls (n = 3), MetS (n = 4) and T2DM (n = 6). Error bars indicate the standard error
of the mean gene expression levels of the individuals within the groups. p-values are indicated for the comparisons between baseline levels,
calculated by unpaired T-test
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Table 7 Characteristics of the groups of patients used for confirmation by real-time pcr
T2DM MetS Obese controls p-value p-value p-value
n = 6 n = 8 n = 4 DM2 vs OC DM2 vs MetS MetS vs OC
Age (years) 59.2 59.9 59.3 p = 0.99 0.82 0.87
Sex (m/f) 6/0 7/1 4/0 1 1 1
Height (cm) 172.2 178.5 178.0 0.10 0.16 0.94
Weight (kg) 84.2 103.2 101.7 0.006 0.09 0.87
BMI (kg/m2) 28.5 32.2 31.7 0.07 0.24 0.94
Waist (cm) 102.1 112.3 118.0 0.02 0.26 0.58
Syst BP (mm Hg) 143.5 137.7 126.5 0.09 0.42 0.09
Diast BP (mm Hg) 85.3 86.3 78.8 0.33 0.76 0.19
FPG (mmol/l) 8.4 6.4 5.5 0.0002 <0.0001 0.008
HbA1c (%) 6.6 5.8 5.4 0.01 0.03 0.22
Tot Chol (mmol/l) 4.8 5.2 5.0 0.79 0.35 0.60
HDL (mmol/l) 1.1 1.6 1.5 0.002 0.007 0.85
LDL (mmol/l) 3 3.1 3.1 0.85 0.69 0.90
TG (mmol/l) 1.9 1.1 0.8 0.04 0.03 0.08
T2DM patients are identical to Table 1, the MetS group is expanded by 4 individuals compared to Table 1. All comparisons were performed by T-test, or Fisher’s
exact for sex. Significant differences (p < 0.05) are indicated in bold. When variances were different, a Welch correction was applied
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titutively expressed ARNT (also termed HIF-1β) and
regulates the response to hypoxia and growth factors by
controlling energy metabolism [59]. Indeed, gene ontol-
ogy analysis confirmed that metabolic processes were
affected in T2DM patients compared to circulating cells
from MetS subjects. Affected metabolic processes have
been demonstrated before in blood cells from T2DM
versus MetS, or versus nondiabetic controls [60, 61],
although the subjects were not matched for BMI as in
our study. It may not be surprising to identify metabolic
processes in metabolically disturbed patients, however it
does indicate that these metabolic changes are reflected
in the gene expression profile of peripheral blood cells
and can thus be monitored. Interestingly, HIF-1α activ-
ity, experimentally induced upon intermittent hypoxia,
increases plasma triglycerides through upregulation of
sterol regulatory element binding protein (SREBP)-1
activity in the liver [62]. These results correspond to our
findings that T2DM patients show higher HIF-1α activity,
associated with higher plasma triglyceride levels. Further-
more, the genes showing higher transcript levels in T2DM
patients not only contained binding sites for HIF-1α and
ARNT, but also for SREBP-1, thus reminiscent of the mo-
lecular switches during hypoxia in the liver.
The previously described reduced expression of genes
involved in electron transport chain and oxidative
phosphorylation in PBMC from T2DM vs young lean
controls [15] is consistent with increased HIF-1α activity
in T2DM. We confirmed the reduced expression of elec-
tron transport chain and oxidative phosphorylation genesin T2DM when we compared these patients to young lean
controls (Additional file 1B). It is quite remarkable that
the analysis of only three controls and six T2DM patients
results in such highly significant pathways which are con-
sistent with previously published data.
It is not quite clear what exactly caused the increased
activity of HIF-1α in T2DM patients. In normal physi-
ology, hypoxia regulates HIF-1α activity on the protein
level by preventing its degradation by an oxygen-
dependent mechanism, reviewed in [63]. However, it
has been suggested before that hyperglycemia mimics
the effects of hypoxia, in terms of an increased cyto-
solic ratio of NADH/NAD+, referred to as pseudo
hypoxia in diabetes patients [64]. Reactive oxygen spe-
cies (ROS) may also stabilize HIF-1α under normoxic
conditions, resulting in increased glycolytic metabolism
and increased NADH/NAD+ ratio [65]. High dietary
fat intake and obesity causes increased release of
skeletal muscle mitochondrial ROS species (H2O2) ac-
companied by a change in redox environment to a
more oxidized state (generally referred to as oxidative
stress) and insulin resistance in mice and humans
[66] Targeting the altered redox state in mice by
neutralization of H2O2 by an antioxidant or by overex-
pression of catalase in mitochondria of muscle cells
prevents high fat diet-induced insulin resistance [66].
The two-fold increased expression of catalase in circu-
lating cells from T2DM patients compared to MetS
suggests that a compensatory mechanism for increased
oxidative damage is activated in T2DM. Therefore, it might
very well be that in T2DM patients, chronic hyperglycemia
Fig. 5 Baseline levels of cytotoxicity-related genes determined by real-time pcr in lean controls, obese controls, MetS and T2DM patients. mRNA
levels of cytotoxicity genes are expressed relative to β-actin as indicated. Error bars indicate the standard error of the mean gene expression levels
of the individuals within the groups. p-values are indicated for the comparisons between baseline levels, calculated by unpaired T-test
van der Pouw Kraan et al. BMC Medical Genomics  (2015) 8:20 Page 14 of 16and oxidative stress contributes to the HIF-1α- regulated
metabolic change in peripheral blood cells. Indeed, pro-
longed high glucose levels in vivo induces the expression
of the HIF-1α-responsive gene VEGF and vascular dysfunc-
tion in rats [67]. Interestingly, adipocyte-specific disruption
of ARNT or disruption of HIF-1α in mice results in similar
metabolic phenotypes. In both mouse models the high
fat diet-induced abnormalities are reduced, including
diminished fat formation, protection from obesity and
insulin resistance [68], suggesting a role for HIF1 in the
pathogenesis of obesity and insulin resistance.
The gene expression profile in peripheral blood seems
to partially mimic the profile of adipocytes, with respect
to HIF-1α activity and leptin expression (both associated
with obesity), and to partially mimic the response in
the liver, reflected by the enriched binding sites for
SREBP-1 normally activated by HIF-1α in the liver.
These findings are in line with the suggestion that
altered gene expression in specific organs, is reflected in
peripheral blood cells [14].Conclusions
Using an unbiased approach we have revealed that a
hyperglycemic state affects the cytotoxic immune
capacity. The reduced cytotoxic potential may render
the T2DM patients less capable to clear viral infec-
tions. This suggestion is supported by the identifica-
tion of a reovirus expression signature in T2DM
patients. It is tempting to speculate that viral infections
in T2DM fuel systemic inflammatory processes and
may even lead to infection of pancreatic beta cells, as
has been shown in experimental animals, and thus
contribute to the induction of insulitis and insulin-
dependent diabetes.Additional files
Additional file 1: Genes expressed at higher levels in T2DM patients
compared to individuals with MetS. Statistical analysis was performed
using the SAM package. A q value <5 % is considered significant.
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compared to individuals with MetS. Statistical analysis was performed
using the SAM package. A q value <5 % is considered significant.
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